Paolo Tarantino shared a post on X:
“New report on the risk of radiation necrosis with concurrent ADCs + brain RT. Incidence of symptomatic radiation necrosis was 27% with concurrent vs. 11% with non-concurrent ADC/RT (p=0.014). Important to temporarily stop the ADC before pursuing brain RT.”
Read further.
Source: Paolo Tarantino/X
Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.